Sirolimus - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (3)Enzymes (3)Transporters (3)

Targets (3)Enzymes (3)Transporters (3)Biointeractions (10)

Identification

Name

Sirolimus

Accession Number

DB00877 (APRD00178, DB02439)

Type

Small Molecule

Groups

Approved, Investigational

Description

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. [PubChem]

Structure

MOL SDF PDB SMILES InChI

Synonyms

(-)-Rapamycin

Rapamycin

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Gd-sirolimus	Tablet	5 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Gd-sirolimus	Tablet	1.0 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Gd-sirolimus	Tablet	2 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Gd-sirolimus	Solution	1.0 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Rapamune	Tablet, coated	2 mg	Oral	Pfizer	2001-03-13	Not applicable	EU
Rapamune	Tablet, sugar coated	1 mg/1	Oral	Cardinal Health	2001-07-01	Not applicable	US
Rapamune	Tablet	2 mg	Oral	Pfizer	Not applicable	Not applicable	Canada
Rapamune	Tablet, coated	1 mg	Oral	Pfizer	2001-03-13	Not applicable	EU
Rapamune	Tablet, coated	0.5 mg	Oral	Pfizer	2001-03-13	Not applicable	EU
Rapamune	Tablet, sugar coated	1 mg/1	Oral	Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.	2001-07-01	Not applicable	US
Rapamune	Solution	1 mg/ml	Oral	Pfizer	2001-03-13	Not applicable	EU
Rapamune	Tablet, coated	2 mg	Oral	Pfizer	2001-03-13	Not applicable	EU
Rapamune	Tablet	5 mg	Oral	Pfizer	Not applicable	Not applicable	Canada
Rapamune	Solution	1 mg/mL	Oral	Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.	1999-09-01	Not applicable	US
Rapamune	Tablet, sugar coated	2 mg/1	Oral	Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.	2001-07-01	Not applicable	US
Rapamune	Tablet, coated	1 mg	Oral	Pfizer	2001-03-13	Not applicable	EU
Rapamune	Tablet, coated	0.5 mg	Oral	Pfizer	2001-03-13	Not applicable	EU
Rapamune	Tablet	1.0 mg	Oral	Pfizer	2003-03-25	Not applicable	Canada
Rapamune	Tablet, sugar coated	.5 mg/1	Oral	Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.	2010-03-01	Not applicable	US
Rapamune Oral Solution	Solution	1.0 mg	Oral	Pfizer	2001-05-15	Not applicable	Canada
Sirolimus	Tablet, sugar coated	.5 mg/1	Oral	Greenstone, Llc	2014-01-07	Not applicable	US
Sirolimus	Tablet, sugar coated	1 mg/1	Oral	Greenstone, Llc	2014-10-27	Not applicable	US
Sirolimus	Tablet, sugar coated	2 mg/1	Oral	Greenstone, Llc	2014-10-27	Not applicable	US

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Sirolimus	Tablet	1 mg/1	Oral	Dr Reddy's Laboratories	2014-10-27	Not applicable	US
Sirolimus	Tablet	1 mg/1	Oral	Amerincan Health Packaging	2015-10-15	Not applicable	US
Sirolimus	Tablet	2 mg/1	Oral	Dr Reddy's Laboratories	2014-10-27	Not applicable	US
Sirolimus	Tablet, film coated	.5 mg/1	Oral	Amerincan Health Packaging	2015-03-31	Not applicable	US
Sirolimus	Tablet, film coated	.5 mg/1	Oral	Cadila Pharnmaceuticals	2014-01-15	Not applicable	US
Sirolimus	Tablet, film coated	.5 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2014-01-15	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

W36ZG6FT64

CAS number

53123-88-9

Weight

Average: 914.1719
Monoisotopic: 913.555141619

Chemical Formula

C₅₁H₇₉NO₁₃

InChI Key

QFJCIRLUMZQUOT-KLHQEZAJSA-N

InChI

InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33+,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1

IUPAC Name

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

SMILES

[H][C@@]1(C[C@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC

Pharmacology

Indication

For the prophylaxis of organ rejection in patients receiving renal transplants.

Structured Indications

Pharmacodynamics

Sirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids.

Mechanism of action

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Serine/threonine-protein kinase mTOR	Protein	yes	inhibitor	Human	P42345	details
Peptidyl-prolyl cis-trans isomerase FKBP1A	Protein	yes	other	Human	P62942	details
Fibroblast growth factor 2	Protein	yes	other/unknown	Human	P09038	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

92%

Metabolism

Substrate	Enzymes	Product
Sirolimus	Cytochrome P450 3A4	41-O-demethylrapamycin	Details

Route of elimination

Not Available

Half life

57-63 hours

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,4-thiazolidinedione	The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Sirolimus.	Investigational
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Sirolimus.	Approved, Investigational
Acebutolol	The serum concentration of Acebutolol can be decreased when it is combined with Sirolimus.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Sirolimus.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Sirolimus.	Withdrawn
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Sirolimus.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Sirolimus.	Approved
AICA ribonucleotide	The therapeutic efficacy of Aicar can be decreased when used in combination with Sirolimus.	Experimental
Aldosterone	The serum concentration of Aldosterone can be decreased when it is combined with Sirolimus.	Experimental
Alitretinoin	The serum concentration of Alitretinoin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Sirolimus.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Sirolimus.	Approved, Investigational
Amiodarone	The metabolism of Sirolimus can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be decreased when it is combined with Sirolimus.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Amlodipine.	Approved
Amphotericin B	The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sirolimus.	Approved, Investigational
Amrinone	The risk or severity of adverse effects can be increased when Sirolimus is combined with Amrinone.	Approved
Apixaban	The serum concentration of Apixaban can be decreased when it is combined with Sirolimus.	Approved
Aprepitant	The serum concentration of Sirolimus can be increased when it is combined with Aprepitant.	Approved, Investigational
Arsenic trioxide	The serum concentration of Arsenic trioxide can be decreased when it is combined with Sirolimus.	Approved, Investigational
Atazanavir	The metabolism of Sirolimus can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be decreased when it is combined with Sirolimus.	Approved
Atomoxetine	The metabolism of Sirolimus can be decreased when combined with Atomoxetine.	Approved
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Sirolimus.	Approved, Investigational
Azelnidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Azelnidipine.	Approved
Azimilide	The risk or severity of adverse effects can be increased when Sirolimus is combined with Azimilide.	Investigational
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Sirolimus.	Investigational
Barnidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Barnidipine.	Approved
BCG vaccine	The therapeutic efficacy of Bcg can be decreased when used in combination with Sirolimus.	Investigational
Benazepril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Benazepril.	Approved, Investigational
Benidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Benidipine.	Approved
Bepridil	The risk or severity of adverse effects can be increased when Sirolimus is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Sirolimus.	Approved, Investigational
Bexarotene	The serum concentration of Sirolimus can be decreased when it is combined with Bexarotene.	Approved, Investigational
Boceprevir	The serum concentration of Sirolimus can be increased when it is combined with Boceprevir.	Approved, Investigational
Bortezomib	The metabolism of Sirolimus can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Sirolimus can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Sirolimus.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Sirolimus.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Sirolimus.	Withdrawn
Buspirone	The metabolism of Buspirone can be decreased when combined with Sirolimus.	Approved, Investigational
Busulfan	The serum concentration of Busulfan can be increased when it is combined with Sirolimus.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sirolimus.	Approved
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Sirolimus.	Approved
Camptothecin	The serum concentration of Camptothecin can be decreased when it is combined with Sirolimus.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Sirolimus.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Candoxatril.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Captopril.	Approved
Carbamazepine	The metabolism of Sirolimus can be increased when combined with Carbamazepine.	Approved, Investigational
Carboxyamidotriazole	The risk or severity of adverse effects can be increased when Sirolimus is combined with Cai.	Investigational
Carfilzomib	The serum concentration of Carfilzomib can be decreased when it is combined with Sirolimus.	Approved
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Sirolimus.	Experimental
Ceritinib	The serum concentration of Sirolimus can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Sirolimus.	Withdrawn
Chlorpromazine	The serum concentration of Chlorpromazine can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Sirolimus.	Approved
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Sirolimus.	Experimental
Cilazapril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Cilnidipine.	Approved
Cimetidine	The serum concentration of Cimetidine can be decreased when it is combined with Sirolimus.	Approved
Cinnarizine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Cinnarizine.	Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Cisapride	The serum concentration of Cisapride can be increased when it is combined with Sirolimus.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be decreased when it is combined with Sirolimus.	Approved
Citalopram	The serum concentration of Citalopram can be decreased when it is combined with Sirolimus.	Approved
Clarithromycin	The metabolism of Sirolimus can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Sirolimus can be decreased when combined with Clemastine.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Clevidipine.	Approved
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Sirolimus.	Approved, Illicit
Clomifene	The serum concentration of Clomifene can be decreased when it is combined with Sirolimus.	Approved, Investigational
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Sirolimus.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be decreased when it is combined with Sirolimus.	Approved, Nutraceutical
Clotrimazole	The metabolism of Sirolimus can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clotrimazole	The serum concentration of Sirolimus can be increased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Clozapine.	Approved
Cobicistat	The metabolism of Sirolimus can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Sirolimus.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Sirolimus.	Approved
Conivaptan	The metabolism of Conivaptan can be decreased when combined with Sirolimus.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Sirolimus.	Approved
Crizotinib	The serum concentration of Sirolimus can be increased when it is combined with Crizotinib.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Sirolimus.	Approved, Investigational
Cyclosporine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclosporine	The metabolism of Sirolimus can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Sirolimus.	Approved
Dabrafenib	The serum concentration of Sirolimus can be decreased when it is combined with Dabrafenib.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be decreased when it is combined with Sirolimus.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Sirolimus.	Approved
Darodipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Darodipine.	Experimental
Darunavir	The metabolism of Sirolimus can be decreased when combined with Darunavir.	Approved
Dasabuvir	The serum concentration of Sirolimus can be increased when it is combined with Dasabuvir.	Approved
Dasatinib	The serum concentration of Sirolimus can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be decreased when it is combined with Sirolimus.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be decreased when it is combined with Sirolimus.	Approved
Deferasirox	The serum concentration of Sirolimus can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Sirolimus can be decreased when combined with Delavirdine.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Sirolimus.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Sirolimus.	Investigational
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Sirolimus.	Approved
Dexamethasone	The serum concentration of Sirolimus can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Sirolimus.	Approved, Illicit, Vet Approved
Didanosine	Didanosine can cause a decrease in the absorption of Sirolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Sirolimus.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Sirolimus.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Sirolimus.	Approved
Dihydroergotamine	The metabolism of Sirolimus can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Sirolimus.	Illicit
Diltiazem	The risk or severity of adverse effects can be increased when Sirolimus is combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Dipyridamole can be decreased when it is combined with Sirolimus.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Sirolimus.	Approved, Investigational
Dofetilide	The metabolism of Dofetilide can be decreased when combined with Sirolimus.	Approved
Domperidone	The serum concentration of Domperidone can be decreased when it is combined with Sirolimus.	Approved, Investigational, Vet Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Sirolimus.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Doxycycline	The metabolism of Sirolimus can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	The metabolism of Sirolimus can be decreased when combined with Dronedarone.	Approved
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Sirolimus.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Sirolimus.	Approved
Efavirenz	The serum concentration of Sirolimus can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efonidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Efonidipine.	Approved
Eletriptan	The serum concentration of Eletriptan can be decreased when it is combined with Sirolimus.	Approved, Investigational
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Sirolimus is combined with Enalaprilat.	Approved
Enzalutamide	The serum concentration of Sirolimus can be decreased when it is combined with Enzalutamide.	Approved
Eperisone	The risk or severity of adverse effects can be increased when Sirolimus is combined with Eperisone.	Approved, Investigational
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Sirolimus.	Approved, Investigational
Erythromycin	The metabolism of Sirolimus can be decreased when combined with Erythromycin.	Approved, Vet Approved
Eslicarbazepine acetate	The serum concentration of Sirolimus can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Sirolimus.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be decreased when it is combined with Sirolimus.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Sirolimus.	Approved
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Sirolimus.	Approved
Etravirine	The serum concentration of Etravirine can be increased when it is combined with Sirolimus.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Sirolimus.	Approved
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Sirolimus.	Approved, Investigational
Ezetimibe	The serum concentration of Ezetimibe can be decreased when it is combined with Sirolimus.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Felodipine.	Approved, Investigational
Fendiline	The risk or severity of adverse effects can be increased when Sirolimus is combined with Fendiline.	Withdrawn
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Sirolimus.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be decreased when it is combined with Sirolimus.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be decreased when it is combined with Sirolimus.	Approved
Fingolimod	Sirolimus may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Fluconazole	The serum concentration of Sirolimus can be increased when it is combined with Fluconazole.	Approved
Flunarizine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Flunarizine.	Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be decreased when it is combined with Sirolimus.	Approved
Fluvoxamine	The metabolism of Sirolimus can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Sirolimus can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Sirolimus can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Fosinopril.	Approved
Fosphenytoin	The serum concentration of Sirolimus can be decreased when it is combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Sirolimus can be increased when it is combined with Fusidic Acid.	Approved
G17DT	The risk or severity of adverse effects can be increased when Sirolimus is combined with G17DT.	Investigational
Gabapentin	The risk or severity of adverse effects can be increased when Sirolimus is combined with Gabapentin.	Approved, Investigational
Gallopamil	The risk or severity of adverse effects can be increased when Sirolimus is combined with Gallopamil.	Investigational
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Sirolimus.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be decreased when it is combined with Sirolimus.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Sirolimus.	Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Sirolimus.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Sirolimus.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Sirolimus.	Approved
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Sirolimus.	Approved
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Sirolimus.	Approved
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Sirolimus.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Sirolimus.	Withdrawn
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Sirolimus.	Investigational
Haloperidol	The serum concentration of Haloperidol can be decreased when it is combined with Sirolimus.	Approved
Hydrocortisone	The serum concentration of Hydrocortisone can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Ibuprofen	The serum concentration of Ibuprofen can be decreased when it is combined with Sirolimus.	Approved
Idelalisib	The serum concentration of Sirolimus can be increased when it is combined with Idelalisib.	Approved
Imatinib	The metabolism of Sirolimus can be decreased when combined with Imatinib.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Imidapril.	Investigational
Imipramine	The serum concentration of Imipramine can be decreased when it is combined with Sirolimus.	Approved
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Sirolimus.	Approved
Indinavir	The metabolism of Sirolimus can be decreased when combined with Indinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be decreased when it is combined with Sirolimus.	Approved, Investigational
INGN 201	The risk or severity of adverse effects can be increased when Sirolimus is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Sirolimus is combined with INGN 225.	Investigational
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Sirolimus.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Sirolimus.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Sirolimus.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Sirolimus.	Approved
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Sirolimus.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Sirolimus.	Approved
Irinotecan	The serum concentration of Irinotecan can be decreased when it is combined with Sirolimus.	Approved, Investigational
Isavuconazonium	The metabolism of Sirolimus can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isradipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Isradipine.	Approved
Itraconazole	The serum concentration of Sirolimus can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Sirolimus can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Josamycin	The metabolism of Sirolimus can be decreased when combined with Josamycin.	Approved
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Sirolimus.	Approved
Ketoconazole	The serum concentration of Sirolimus can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoconazole	The metabolism of Sirolimus can be decreased when combined with Ketoconazole.	Approved, Investigational
Kitasamycin	The metabolism of Sirolimus can be decreased when combined with Kitasamycin.	Experimental
Lacidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Lacidipine.	Approved
Lamivudine	The serum concentration of Lamivudine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Lamotrigine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Lamotrigine.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be decreased when it is combined with Sirolimus.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Sirolimus.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Sirolimus is combined with Leflunomide.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be decreased when it is combined with Sirolimus.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be decreased when it is combined with Sirolimus.	Approved
Lercanidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Lercanidipine.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be decreased when it is combined with Sirolimus.	Approved, Investigational
Levofloxacin	The serum concentration of Levofloxacin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be decreased when it is combined with Sirolimus.	Approved
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Sirolimus.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Sirolimus.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Lisinopril.	Approved, Investigational
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Sirolimus.	Approved
Lopinavir	The metabolism of Sirolimus can be decreased when combined with Lopinavir.	Approved
Losartan	The metabolism of Losartan can be decreased when combined with Sirolimus.	Approved
Lovastatin	The metabolism of Sirolimus can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Sirolimus can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Sirolimus can be increased when combined with Lumacaftor.	Approved
Magnesium Sulfate	The risk or severity of adverse effects can be increased when Sirolimus is combined with Magnesium Sulfate.	Approved, Vet Approved
Manidipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Manidipine.	Approved
Mannitol	The serum concentration of Mannitol can be decreased when it is combined with Sirolimus.	Approved, Investigational
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Sirolimus.	Withdrawn
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus.	Approved
Methotrexate	The serum concentration of Methotrexate can be decreased when it is combined with Sirolimus.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Metoprolol	The serum concentration of Metoprolol can be decreased when it is combined with Sirolimus.	Approved, Investigational
Mibefradil	The risk or severity of adverse effects can be increased when Sirolimus is combined with Mibefradil.	Withdrawn
Midazolam	The serum concentration of Midazolam can be decreased when it is combined with Sirolimus.	Approved, Illicit
Mifepristone	The serum concentration of Sirolimus can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Sirolimus.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Sirolimus.	Approved
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Sirolimus.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Sirolimus.	Approved, Investigational
Mitotane	The serum concentration of Sirolimus can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be decreased when it is combined with Sirolimus.	Approved, Investigational
Modafinil	The serum concentration of Sirolimus can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Moexipril.	Approved
Morphine	The serum concentration of Morphine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Sirolimus.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be decreased when it is combined with Sirolimus.	Approved
Nafcillin	The serum concentration of Sirolimus can be decreased when it is combined with Nafcillin.	Approved
Naftopidil	The risk or severity of adverse effects can be increased when Sirolimus is combined with Naftopidil.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Sirolimus.	Approved
Naloxone	The serum concentration of Naloxone can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Natalizumab	The risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.	Approved, Investigational
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Sirolimus.	Approved, Investigational
Nefazodone	The metabolism of Sirolimus can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Sirolimus can be increased when it is combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Sirolimus can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Sirolimus can be increased when combined with Nevirapine.	Approved
Nicardipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Nicardipine.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Nifedipine.	Approved
Niguldipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Niguldipine.	Experimental
Nilotinib	The metabolism of Sirolimus can be decreased when combined with Nilotinib.	Approved, Investigational
Niludipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Niludipine.	Experimental
Nilvadipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Nilvadipine.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Sirolimus is combined with Nimesulide.	Approved, Withdrawn
Nimodipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Nimodipine.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Sirolimus.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Nisoldipine.	Approved
Nitrendipine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Nitrendipine.	Approved
Nizatidine	The serum concentration of Nizatidine can be decreased when it is combined with Sirolimus.	Approved
Olanzapine	The serum concentration of Olanzapine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Olaparib	The metabolism of Sirolimus can be decreased when combined with Olaparib.	Approved
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Sirolimus.	Experimental
Omapatrilat	The risk or severity of adverse effects can be increased when Sirolimus is combined with Omapatrilat.	Investigational
Ombitasvir	The serum concentration of Sirolimus can be increased when it is combined with Ombitasvir.	Approved
Osimertinib	The serum concentration of Sirolimus can be increased when it is combined with Osimertinib.	Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Sirolimus.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sirolimus.	Approved, Vet Approved
Palbociclib	The serum concentration of Sirolimus can be increased when it is combined with Palbociclib.	Approved
Panobinostat	The serum concentration of Panobinostat can be decreased when it is combined with Sirolimus.	Approved, Investigational
Paritaprevir	The serum concentration of Sirolimus can be increased when it is combined with Paritaprevir.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Sirolimus.	Approved
Pentobarbital	The metabolism of Sirolimus can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perhexiline	The risk or severity of adverse effects can be increased when Sirolimus is combined with Perhexiline.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Perindopril.	Approved
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Sirolimus.	Approved, Withdrawn
Phenobarbital	The metabolism of Sirolimus can be increased when combined with Phenobarbital.	Approved
Phenytoin	The serum concentration of Sirolimus can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Picosulfuric acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sirolimus.	Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sirolimus.	Approved, Investigational
Pimozide	Sirolimus may increase the arrhythmogenic activities of Pimozide.	Approved
Pinaverium	The risk or severity of adverse effects can be increased when Sirolimus is combined with Pinaverium.	Approved
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Sirolimus.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Sirolimus.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Sirolimus.	Approved
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Sirolimus.	Approved
Posaconazole	The serum concentration of Sirolimus can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Sirolimus.	Approved, Investigational
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Sirolimus.	Approved
Prazosin	The serum concentration of Prazosin can be decreased when it is combined with Sirolimus.	Approved
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Sirolimus is combined with Pregabalin.	Approved, Illicit, Investigational
Prenylamine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Prenylamine.	Withdrawn
Primidone	The metabolism of Sirolimus can be increased when combined with Primidone.	Approved, Vet Approved
Progesterone	The therapeutic efficacy of Progesterone can be decreased when used in combination with Sirolimus.	Approved, Vet Approved
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Sirolimus.	Approved, Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Sirolimus.	Approved
Quetiapine	The serum concentration of Quetiapine can be decreased when it is combined with Sirolimus.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Quinapril.	Approved, Investigational
Quinidine	The metabolism of Quinidine can be decreased when combined with Sirolimus.	Approved
Quinine	The serum concentration of Quinine can be decreased when it is combined with Sirolimus.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Ramipril.	Approved
Ranitidine	The serum concentration of Ranitidine can be decreased when it is combined with Sirolimus.	Approved
Ranolazine	The metabolism of Ranolazine can be decreased when combined with Sirolimus.	Approved, Investigational
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Sirolimus.	Approved, Investigational
Rescinnamine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Rescinnamine.	Approved
Reserpine	The serum concentration of Reserpine can be decreased when it is combined with Sirolimus.	Approved
Rifabutin	The metabolism of Sirolimus can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Sirolimus can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Sirolimus can be increased when combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Sirolimus.	Approved, Investigational
Rindopepimut	The risk or severity of adverse effects can be increased when Sirolimus is combined with CDX-110.	Investigational
Risedronate	The risk or severity of adverse effects can be increased when Sirolimus is combined with Risedronate.	Approved, Investigational
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Sirolimus.	Approved, Investigational
Ritonavir	The serum concentration of Sirolimus can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be decreased when it is combined with Sirolimus.	Approved
Roflumilast	Roflumilast may increase the immunosuppressive activities of Sirolimus.	Approved
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Sirolimus.	Approved, Investigational
Salicylic acid	The serum concentration of Salicylic acid can be decreased when it is combined with Sirolimus.	Approved, Vet Approved
Saquinavir	The metabolism of Sirolimus can be decreased when combined with Saquinavir.	Approved, Investigational
Saxagliptin	The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Sirolimus.	Approved
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Sirolimus.	Approved
Sildenafil	The metabolism of Sirolimus can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Sirolimus.	Approved
Siltuximab	The serum concentration of Sirolimus can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Sirolimus can be increased when it is combined with Simeprevir.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sirolimus.	Approved
Sitagliptin	The serum concentration of Sitagliptin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Sirolimus.	Approved
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Sirolimus.	Approved
Solithromycin	The metabolism of Sirolimus can be decreased when combined with Solithromycin.	Investigational
Sorafenib	The serum concentration of Sorafenib can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Sirolimus.	Approved
Sphingosine	The serum concentration of Sphingosine can be decreased when it is combined with Sirolimus.	Experimental
Spirapril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Spirapril.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Sirolimus is combined with SRP 299.	Investigational
St. John's Wort	The serum concentration of Sirolimus can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Sirolimus can be increased when it is combined with Stiripentol.	Approved
Sucralfate	Sucralfate can cause a decrease in the absorption of Sirolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Sulfisoxazole	The metabolism of Sirolimus can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Sirolimus.	Approved, Investigational
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Sirolimus.	Approved, Investigational
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sirolimus.	Approved, Investigational
Tacrolimus	The serum concentration of Tacrolimus can be decreased when it is combined with Sirolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Sirolimus.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be decreased when it is combined with Sirolimus.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Sirolimus.	Approved
Telaprevir	The serum concentration of Sirolimus can be increased when it is combined with Telaprevir.	Withdrawn
Telithromycin	The metabolism of Sirolimus can be decreased when combined with Telithromycin.	Approved
Temocapril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Temocapril.	Experimental, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Sirolimus.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be decreased when it is combined with Sirolimus.	Approved
Ticlopidine	The metabolism of Sirolimus can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be decreased when it is combined with Sirolimus.	Approved
Tocilizumab	The serum concentration of Sirolimus can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Sirolimus may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Sirolimus.	Approved
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Sirolimus.	Approved
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Sirolimus is combined with Tolfenamic Acid.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Sirolimus.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Sirolimus.	Approved, Investigational
Toremifene	The serum concentration of Toremifene can be decreased when it is combined with Sirolimus.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Sirolimus is combined with Trandolapril.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Sirolimus is combined with Tranilast.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Sirolimus.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Sirolimus.	Approved
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Sirolimus.	Withdrawn
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Sirolimus.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be decreased when it is combined with Sirolimus.	Approved
Vecuronium	The serum concentration of Vecuronium can be decreased when it is combined with Sirolimus.	Approved
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Sirolimus.	Approved
Venlafaxine	The metabolism of Sirolimus can be decreased when combined with Venlafaxine.	Approved
Verapamil	The risk or severity of adverse effects can be increased when Sirolimus is combined with Verapamil.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Sirolimus.	Approved, Investigational
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Sirolimus.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Vinpocetine	The risk or severity of adverse effects can be increased when Sirolimus is combined with Vinpocetine.	Investigational
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Sirolimus.	Approved
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Sirolimus.	Approved, Investigational
Voriconazole	The serum concentration of Sirolimus can be increased when it is combined with Voriconazole.	Approved, Investigational
Xylometazoline	The risk or severity of adverse effects can be increased when Sirolimus is combined with Xylometazoline.	Approved
Ziconotide	The risk or severity of adverse effects can be increased when Sirolimus is combined with Ziconotide.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Sirolimus.	Approved
Ziprasidone	The metabolism of Sirolimus can be decreased when combined with Ziprasidone.	Approved
Zolpidem	The serum concentration of Zolpidem can be increased when it is combined with Sirolimus.	Approved

Food Interactions

Not Available

References

Synthesis Reference

Madhup K. Dhaon, Chi-nung Hsiao, Subhash R. Patel, Peter J. Bonk, Sanjay R. Chemburkar, Yong Y. Chen, "One pot synthesis of tetrazole derivatives of sirolimus." U.S. Patent US20080167335, issued July 10, 2008.

US20080167335

General References

Pritchard DI: Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005 May 15;10(10):688-91. [PubMed:15896681 ]
Shuchman M: Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med. 2006 Nov 9;355(19):1949-52. [PubMed:17093244 ]
Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005 Aug 15;65(16):7052-8. [PubMed:16103051 ]
Chan S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004 Oct 18;91(8):1420-4. [PubMed:15365568 ]
Graziani EI: Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Nat Prod Rep. 2009 May;26(5):602-9. doi: 10.1039/b804602f. Epub 2009 Mar 5. [PubMed:19387497 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15015
KEGG Drug	D00753
KEGG Compound	C07909
PubChem Compound	5460439
PubChem Substance	46505675
ChemSpider	21864757
BindingDB	50240955
ChEBI	9168
ChEMBL	CHEMBL413
Therapeutic Targets Database	DNC001197
PharmGKB	PA451365
HET	RAP
Drug Product Database	12064
RxList	http://www.rxlist.com/cgi/generic2/sirolimus.htm
Drugs.com	http://www.drugs.com/cdi/sirolimus.html
Wikipedia	Sirolimus

ATC Codes

S01XA23 — Sirolimus

L04AA10 — Sirolimus

AHFS Codes

92:00.00

PDB Entries

1FKB
1J4I

FDA label

Download (480 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Treatment	Acute Kidney Injury (AKI)	1
0	Active Not Recruiting	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia	1
0	Completed	Treatment	Invasive Bladder Cancer Stage II	1
0	Completed	Treatment	Plasma Cell Myeloma	1
0	Completed	Treatment	Transplantation, Stem Cell	1
0	Completed	Treatment	Tumors, Solid	1
0	Recruiting	Treatment	Bladder Cancers	1
0	Terminated	Treatment	Pemphigus	1
1	Active Not Recruiting	Treatment	Astrocytomas / Atypical Teratoid/Rhabdoid Tumor / Clear Cell Sarcoma of Soft Tissue / Ependymomas / Ewing's Sarcoma (ES) / Germ Cell Tumors / Gliomas / Hepatoblastomas / Medulloblastomas / Neuroblastomas / Renal Cell Adenocarcinoma / Retinoblastoma / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic / Wilms' tumor	1
1	Active Not Recruiting	Treatment	Cancer of Kidney / Cancer of Liver / Malignant Lymphomas / Neoplasms, Breast / Neoplasms, Lung	1
1	Active Not Recruiting	Treatment	Cancer, Advanced	1
1	Active Not Recruiting	Treatment	Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Epithelial Cancer / Stage IIA Primary Peritoneal Cavity Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Epithelial Cancer / Stage IIB Primary Peritoneal Cavity Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Epithelial Cancer / Stage IIC Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Primary Peritoneal Cavity Cancer	1
1	Active Not Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1	Active Not Recruiting	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma	1
1	Completed	Not Available	Acute Lymphoblastic Leukaemias (ALL)	1
1	Completed	Not Available	Advanced Solid Tumors / Refractory to Standard Therapies	1
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Sirolimus	1
1	Completed	Basic Science	Drug Interactions / Hypercholesterolaemia / Immunosuppression / Pharmacokinetics	1
1	Completed	Basic Science	Sarcopenia	1
1	Completed	Prevention	Immunosuppression / Kidney Failure,Chronic / Transplantation, Kidney	1
1	Completed	Prevention	Neoplastic Syndrome / Non-Melanomatous Skin Cancer	1
1	Completed	Treatment	AML / CML / Leukemias / Myeloid Leukemias	1
1	Completed	Treatment	Acute Myeloid Leukaemias (AML)	1
1	Completed	Treatment	Advanced Cancers	1
1	Completed	Treatment	Advanced Solid Tumors	1
1	Completed	Treatment	Aging / CAD	1
1	Completed	Treatment	Allogeneic Stem Cell Transplantation / Malignancies, Hematologic	1
1	Completed	Treatment	Anaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Estrogen Receptor Negative / Estrogen Receptor Positive / Glioblastomas / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Metastatic Renal Cell Cancer / Recurrent Adult Brain Neoplasm / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Hepatocellular Carcinoma / Recurrent Lung Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Prostate Carcinoma / Recurrent Uterine Corpus Carcinoma / Renal Cell Carcinoma Recurrent / Resectable Hepatocellular Carcinoma / Sarcomas / Stage IA Breast Cancer / Stage IA Ovarian Cancer / Stage IA Uterine Corpus Cancer / Stage IB Breast Cancer / Stage IB Ovarian Cancer / Stage IB Uterine Corpus Cancer / Stage IC Ovarian Cancer / Stage II Uterine Corpus Cancer / Stage IIA Breast Cancer / Stage IIA Lung Carcinoma / Stage IIA Ovarian Cancer / Stage IIB Breast Cancer / Stage IIB Esophageal Cancer / Stage IIB Lung Carcinoma / Stage IIB Ovarian Cancer / Stage IIB Skin Melanoma / Stage IIC Ovarian Cancer / Stage IIC Skin Melanoma / Stage IIIA Breast Cancer / Stage IIIA Esophageal Cancer / Stage IIIA Lung Carcinoma / Stage IIIA Ovarian Cancer / Stage IIIA Skin Melanoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Breast Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Skin Melanoma / Stage IIIB Uterine Corpus Cancer / Stage IIIC Breast Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Skin Melanoma / Stage IIIC Uterine Corpus Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Esophageal Cancer / Stage IV Ovarian Cancer / Stage IV Prostate Cancer / Stage IV Skin Melanoma / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer	1
1	Completed	Treatment	Anterior Uveitis (AU)	1
1	Completed	Treatment	Brain and Central Nervous System Tumors	1
1	Completed	Treatment	Cancer, Advanced	4
1	Completed	Treatment	Cancer, Advanced / Metastatic Cancers	1
1	Completed	Treatment	Childhood Solid Tumors / Malignant Solid Tumours	1
1	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	1
1	Completed	Treatment	Diabetic Macular Edema (DME) / Retinopathy, Diabetic	1
1	Completed	Treatment	Drug/Agent Toxicity by Tissue/Organ / Multiple Myeloma and Plasma Cell Neoplasm	1
1	Completed	Treatment	Facial Angiofibroma	1
1	Completed	Treatment	Glioblastomas	1
1	Completed	Treatment	Graft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Transplantation, Homologous	1
1	Completed	Treatment	Healthy Volunteers	2
1	Completed	Treatment	Hepatic Complications	1
1	Completed	Treatment	Hepatocellular,Carcinoma / Rapamycin	1
1	Completed	Treatment	Kidney Diseases	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms	1
1	Completed	Treatment	Liver Cancer	1
1	Completed	Treatment	Low-Grade Gliomas	1
1	Completed	Treatment	Lymphangioleiomyomatosis	1
1	Completed	Treatment	Neoplasms Metastasis / Tumors	1
1	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
1	Completed	Treatment	Pachyonychia Congenita	1
1	Completed	Treatment	Rejection, Transplant / Transplantation, Renal	1
1	Completed	Treatment	Sarcomas	1
1	Completed	Treatment	Tumors, Central Nervous System / Tumors, Solid	1
1	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	1
1	Not Yet Recruiting	Treatment	Pompe's Disease	1
1	Not Yet Recruiting	Treatment	Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer	1
1	Recruiting	Basic Science	Aging	1
1	Recruiting	Treatment	Advanced Cancers	1
1	Recruiting	Treatment	Clear Cell Carcinoma / Ewing's Sarcoma (ES) / Gastrointestinal Tumors / Germ Cell Tumors / Hepatic Tumors / Malignant Lymphomas / Melanoma / Neuroblastomas / Non-rhabdomyosarcoma / Renal Cell Adenocarcinoma / Rhabdoid Tumors / Rhabdomyosarcomas / Wilms' tumor	1
1	Recruiting	Treatment	Sickle Cell Disorders	1
1	Recruiting	Treatment	Sickle Cell-thalassemia Disease / Thalassaemic disorders	1
1	Suspended	Treatment	Acinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Terminated	Treatment	Advanced Solid Cancers	1
1	Terminated	Treatment	Eosinophilic Gastroenteritis / Oesophagitis, Eosinophilic	1
1	Terminated	Treatment	Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Smith-Magenis Syndrome	1
1	Terminated	Treatment	Leukemias / Malignant Lymphomas	1
1	Terminated	Treatment	Leukemias / Malignant Lymphomas / Plasma Cell Myeloma	1
1	Terminated	Treatment	Tumors	1
1	Unknown Status	Treatment	Cardiac Hypertrophy / Immunosuppression	1
1	Unknown Status	Treatment	Diffuse posterior uveitis / Panuveitis / Uveitis / Uveitis, Intermediate	1
1	Unknown Status	Treatment	Refractory Solid Tumors in Children	1
1	Withdrawn	Supportive Care	Acute myeloid leukaemia (in remission) / Primary Myelofibrosis / Primary Myelofibrosis, Prefibrotic Stage / Secondary Acute Myeloid Leukemia / Secondary Myelofibrosis	1
1	Withdrawn	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1	Withdrawn	Treatment	Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Withdrawn	Treatment	Recurrent Non-small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1, 2	Active Not Recruiting	Treatment	Alemtuzumab (Campath ) / Graft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Sickle Cell Disorders / Sirolimus (Rapamune )	1
1, 2	Active Not Recruiting	Treatment	Anemia, Hemolytic, Autoimmune / Autoimmune Lymphoproliferative Syndrome (ALPS) / Autoimmune Neutropenia / Autoimmune Pancytopenia / Evans Syndrome / Idiopathic Thrombocytopenic Purpura (ITP) / Inflammatory Bowel Diseases (IBD) / Lupus Erythematosus, Systemic / Rheumatoid Arthritis	1
1, 2	Active Not Recruiting	Treatment	Malignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
1, 2	Active Not Recruiting	Treatment	Rectum Cancer	1
1, 2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1, 2	Completed	Treatment	Advanced Soft Tissue Sarcoma	1
1, 2	Completed	Treatment	Age-Related Macular Degeneration (ARMD)	1
1, 2	Completed	Treatment	Age-Related Macular Degeneration (ARMD) / Dry Macular Degeneration	1
1, 2	Completed	Treatment	Brain and Central Nervous System Tumors	1
1, 2	Completed	Treatment	CNI Side Effects	1
1, 2	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	1
1, 2	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1 / Hypoglycemia	1
1, 2	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
1, 2	Completed	Treatment	Kidney Diseases / Renal Failure / Transplantation, Kidney	1
1, 2	Completed	Treatment	Kidney Diseases / Transplantation, Kidney	1
1, 2	Completed	Treatment	Malignancies, Hematologic / Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Mouth Neoplasms / Neoplasms, Head and Neck / Squamous Cell Carcinoma (SCC) / Tongue Neoplasms	1
1, 2	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1, 2	Completed	Treatment	Polycystic Kidney Diseases	1
1, 2	Completed	Treatment	Recurrent Bladder Carcinoma / Stage II Bladder Cancer / Stage III Bladder Cancer / Stage IV Bladder Cancer	1
1, 2	Completed	Treatment	Retinopathy, Diabetic	1
1, 2	Completed	Treatment	Scleritis	1
1, 2	Completed	Treatment	Sclerosis, Progressive Systemic	1
1, 2	Not Yet Recruiting	Prevention	Graft Versus Host Disease (GVHD) / Lung Cancers	1
1, 2	Not Yet Recruiting	Treatment	Dermal Atrophy	1
1, 2	Recruiting	Prevention	Adult Hodgkin Lymphoma / Adult Myelodysplastic Syndrome / Agnogenic Myeloid Metaplasia / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Hodgkin Lymphoma / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Non-Hodgkin's lymphoma	1
1, 2	Recruiting	Treatment	Adenocarcinoma of the Lung / Extensive Stage Small Cell Lung Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Small Cell Lung Carcinoma / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
1, 2	Recruiting	Treatment	Castration Levels of Testosterone / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Desmoid Tumors	1
1, 2	Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
1, 2	Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Sickle Cell Disorders / Thalassaemic disorders / Transplantation, Stem Cell	1
1, 2	Recruiting	Treatment	HIV-1 Infections	1
1, 2	Recruiting	Treatment	Hyperinsulinism	1
1, 2	Recruiting	Treatment	Leukemias / Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Malignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas	1
1, 2	Recruiting	Treatment	Pancreatic Adenocarcinoma Metastatic	1
1, 2	Recruiting	Treatment	Sickle Cell Disorders	2
1, 2	Terminated	Treatment	Age-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization	1
1, 2	Terminated	Treatment	Disseminated Sclerosis / Relapsing Remitting Multiple Sclerosis (RRMS)	1
1, 2	Terminated	Treatment	Graft Versus Host Disease (GVHD)	1
1, 2	Unknown Status	Treatment	Aplastic Anaemia (AA)	1
1, 2	Unknown Status	Treatment	End-Stage Renal Disease (ESRD) / Renal Failure	1
1, 2	Withdrawn	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
1, 2	Withdrawn	Treatment	Lung Cancers	1
1, 2	Withdrawn	Treatment	Multiple Myeloma (MM) / Refractory Multiple Myeloma	1
2	Active Not Recruiting	Prevention	Graft Versus Host Disease (GVHD)	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3- / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Lymphoma / Childhood Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Burkitt Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Burkitt Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Contiguous Immunoblastic Lymphoma / Stage II Adult Non-Contiguous Immunoblastic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Burkitt Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Burkitt Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Burkitt Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Burkitt Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Burkitt Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Active Not Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia	1
2	Active Not Recruiting	Treatment	Capillary Lymphatic Arterial Venous Malformations / Capillary Venous Lymphatic Malformation / Kaposiform Hemangioendotheliomas / Lymphangiectasia Syndromes / Microcystic Lymphatic Malformation / Mucocutaneous Lymphangiomatosis and Thrombocytopenia / PTEN Overgrowth Syndrome With Vascular Anomaly / Tufted Angioma / Venous Lymphatic Malformation	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas	1
2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition	1
2	Active Not Recruiting	Treatment	Engraftment Syndrome / Graft Versus Host Disease (GVHD) / Renal Cell Adenocarcinoma	1
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD)	2
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Leukemias / Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Sickle Cell Disorders	2
2	Completed	Not Available	Sturge - Weber Syndrome (SWS)	1
2	Completed	Prevention	Acute Graft Versus Host Disease	1
2	Completed	Prevention	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Prevention	Acute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Malignancies, Hematologic / Myelodysplastic Syndrome / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Prevention	Blood and Marrow Transplant (BMT) / Leukemias / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Prevention	Diabetes, Diabetes Mellitus Type 1	1
2	Completed	Prevention	Immunosuppression / Kidney Failure,Chronic / Transplantation, Kidney	1
2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer	1
2	Completed	Supportive Care	Graft Versus Host Disease (GVHD)	1
2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
2	Completed	Treatment	Acute Myeloid Leukaemias (AML)	1
2	Completed	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia	1
2	Completed	Treatment	Age-Related Macular Degeneration (ARMD)	1
2	Completed	Treatment	Age-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization	1
2	Completed	Treatment	Angiofibromas / Tuberous Sclerosis	1
2	Completed	Treatment	Aplastic Anaemia (AA)	1
2	Completed	Treatment	Autism, Early Infantile / Self-injury / Tuberous Sclerosis Complex (TSC)	1
2	Completed	Treatment	Blood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)	1
2	Completed	Treatment	Cancer, Breast	1
2	Completed	Treatment	Cowden's Disease / Hamartoma Syndrome, Multiple	1
2	Completed	Treatment	Diabetes Mellitus, Insulin-Dependent	1
2	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	2
2	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1 / Hypoglycemia / Metabolic Diseases	1
2	Completed	Treatment	Diabetic Macular Edema (DME)	1
2	Completed	Treatment	Disorder Related to Renal Transplantation	1
2	Completed	Treatment	Exudative Age Related Macular Degeneration	1
2	Completed	Treatment	Eye Dryness	1
2	Completed	Treatment	Glioblastomas / Gliosarcoma	1
2	Completed	Treatment	Glomerulonephritis, Membranous / Lupus Membranous Nepropathy	1
2	Completed	Treatment	Glomerulosclerosis, Focal Segmental	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Malignancies, Hematologic	1
2	Completed	Treatment	H1N1 Pneumonia / Hypoxemia	1
2	Completed	Treatment	Hepatocellular,Carcinoma	1
2	Completed	Treatment	Hodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	Kidney, Polycystic	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes	1
2	Completed	Treatment	Lymphangioleiomyomatosis / Tuberous Sclerosis	1
2	Completed	Treatment	Malignant Neoplasm of Pancreas	2
2	Completed	Treatment	Neurofibromatosis 2	1
2	Completed	Treatment	Neurofibromatosis Type 1	1
2	Completed	Treatment	Renal Cell Adenocarcinoma	1
2	Completed	Treatment	Renal Failure	1
2	Completed	Treatment	Sarcoma, Osteogenic	1
2	Completed	Treatment	Sarcomas	1
2	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
2	Completed	Treatment	Transplantation, Kidney	3
2	Recruiting	Not Available	Depressive State	1
2	Recruiting	Basic Science	Aging	1
2	Recruiting	Basic Science	Cancer of Breast	1
2	Recruiting	Basic Science	Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia	1
2	Recruiting	Prevention	Acute Leukemia in Remission / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Primary Myelofibrosis	1
2	Recruiting	Prevention	End Stage Renal Disease (ESRD) / Venous Stenosis	1
2	Recruiting	Prevention	Graft Versus Host Disease (GVHD)	1
2	Recruiting	Prevention	Graft Versus Host Disease (GVHD) / Haematological Malignancies	1
2	Recruiting	Supportive Care	Chronic Graft Versus Host Disease / Oral Mucosal Disease Due to Graft-versus-host Disease	1
2	Recruiting	Treatment	Acute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma / Acute Myelogenous Leukaemia (AML) / Acute Undifferentiated Leukemia (AUL) / Chemotherapy-sensitive Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndromes (MDS)	1
2	Recruiting	Treatment	Acute GVHD	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukemia/Lymphoma / Acute Myeloid Leukaemias (AML) / Biphenotypic/Undifferentiated/Prolymphocytic Leukemias / Bone Marrow Failure Syndromes / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Leukemia or MDS in Aplasia / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Hodgkins / Lymphoma, Large-Cell / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone B-Cell Lymphoma / MRD Positive Leukemia / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms/Myelofibrosis / Myeloproliferative Syndromes / Natural Killer Cell Malignancies / Recurrent Cutaneous T-cell lymphoma / Relapsed Chronic Lymphocytic Leukemia / Relapsed Multiple Myeloma / Relapsed Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)	1
2	Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia in Remission / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome	1
2	Recruiting	Treatment	Adenomatous Polyposis Coli	1
2	Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Adult Myelodysplastic Syndrome / Adult Non-Hodgkin's Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Diffuse Large B -Cell Lymphoma / Childhood Myelodysplastic Syndrome / Childhood Non-Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia in Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Leukemia, Prolymphocytic / Mantle Cell Lymphoma (MCL) / Plasma Cell Myeloma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)	1
2	Recruiting	Treatment	Aplastic Anaemia (AA) / Immunodeficiency Syndrome / Non-Cancer Diagnosis / Severe Aplastic Anemia (SAA)	1
2	Recruiting	Treatment	Arteriovenous Malformations / Arteriovenous Malformations (Stage II to IV)	1
2	Recruiting	Treatment	Cancers	1
2	Recruiting	Treatment	Cancers / Leukemias / Malignant Lymphomas	1
2	Recruiting	Treatment	Chondrosarcoma, Mesenchymal / Conventional Chondrosarcoma / Dedifferentiated Chondrosarcoma / Myxoid Liposarcoma	1
2	Recruiting	Treatment	Congenital Hemolytic Anemia / Congenital Hypoplastic Anemia	1
2	Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	2
2	Recruiting	Treatment	Epidermolysis Bullosa Simplex / Epidermolysis Bullosa Simplex Kobner / Weber-Cockayne Syndrome	2
2	Recruiting	Treatment	Genetics / Growth Disorders / PIK3CA-Related Overgrowth Spectrum (PROS)	1
2	Recruiting	Treatment	HHV-8 / HIV Disease / Lymphoproliferative Disorders / Malignancies	1
2	Recruiting	Treatment	Haemangioma-thrombocytopenia syndrome / Kaposiform Hemangioendothelioma (KHE) / Tufted Angioma	1
2	Recruiting	Treatment	In-stent Stenosis / Peripheral Pulmonary Stenosis	1
2	Recruiting	Treatment	Kaposiform Hemangioendothelioma / Kasabach Merritt Phenomenon	1
2	Recruiting	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myeloproliferative Disorders	1
2	Recruiting	Treatment	Metastatic Thyroid Cancer	1
2	Recruiting	Treatment	Neuroblastoma Recurrent	1
2	Recruiting	Treatment	Pinealoblastoma	1
2	Recruiting	Treatment	Recurrent Implantation Failure (RIF)	1
2	Recruiting	Treatment	Refractory and/or Relapsed Metastatic Solid Tumors	1
2	Recruiting	Treatment	Relapsed / Recurrent Germ Cell Tumors	1
2	Recruiting	Treatment	Segmental Overgrowth Disorders Due to PIK3CA	1
2	Recruiting	Treatment	Severe Aplastic Anemia (SAA)	1
2	Recruiting	Treatment	Sickle Cell Disorders	2
2	Recruiting	Treatment	Vascular Malformations	1
2	Terminated	Prevention	Acute Leukemia in Remission / Leukemia, Myeloid, Accelerated-Phase / Leukemia, Myeloid, Chronic-Phase / Myelodysplastic Syndromes	1
2	Terminated	Prevention	Graft Versus Host Disease (GVHD)	1
2	Terminated	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Terminated	Treatment	Age-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization	1
2	Terminated	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2	Terminated	Treatment	Dry Macular Degeneration	1
2	Terminated	Treatment	End-Stage Renal Disease (ESRD)	1
2	Terminated	Treatment	Haematological Malignancies / Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome	1
2	Terminated	Treatment	Hematologic Diseases	1
2	Terminated	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Terminated	Treatment	Sarcomas	1
2	Terminated	Treatment	Squamous Cell Skin Carcinoma	1
2	Terminated	Treatment	Transplant, Kidney	1
2	Unknown Status	Prevention	Acute Graft-Versus-Host Disease / Chronic Graft Versus Host Disease / Steroid Refractory Graft-Versus-Host Disease	1
2	Unknown Status	Treatment	Lymphangioleiomyomatosis / Tuberous Sclerosis	1
2	Unknown Status	Treatment	Nonmalignant Neoplasm	1
2	Unknown Status	Treatment	Transplantation, Liver	1
2	Withdrawn	Prevention	Hematopoietic Stem Cell Transplant (HSCT) / Severe Combined Immunodeficiency / Transplacental Maternal Engraftment	1
2	Withdrawn	Treatment	Cutaneous T-Cell Lymphoma (CTCL)	1
2	Withdrawn	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2, 3	Active Not Recruiting	Treatment	Chronic Graft Versus Host Disease	1
2, 3	Active Not Recruiting	Treatment	Inclusion Body Myositis (IBM)	1
2, 3	Active Not Recruiting	Treatment	Transplantation, Kidney	1
2, 3	Completed	Treatment	Hepatocellular,Carcinoma	1
2, 3	Recruiting	Treatment	Congenital Hypoplastic Anemia	1
2, 3	Recruiting	Treatment	Liver Diseases	1
2, 3	Recruiting	Treatment	Sturge-Weber Syndrome	1
2, 3	Terminated	Treatment	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	2
2, 3	Terminated	Treatment	Hypertensive	1
2, 3	Unknown Status	Treatment	Polycystic Kidney Diseases	1
2, 3	Withdrawn	Treatment	Malignant Neoplasm of Prostate	1
3	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hodgkin Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-cell chronic lymphocytic leukaemia / Waldenstrom's Macroglobulinemia (WM)	1
3	Active Not Recruiting	Treatment	B-cell Childhood Acute Lymphoblastic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Graft Versus Host Disease (GVHD) / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	Non-Infectious Uveitis of the Posterior Segment of the Eye	1
3	Completed	Not Available	Graft Versus Host Disease (GVHD) / Transplantation, Kidney	1
3	Completed	Prevention	Graft Versus Host Disease (GVHD) / Survival	1
3	Completed	Prevention	Kidney Diseases	1
3	Completed	Prevention	Renal Allograft Recipients	1
3	Completed	Prevention	Transplant, Kidney	1
3	Completed	Prevention	Transplantation, Renal	1
3	Completed	Treatment	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	1
3	Completed	Treatment	Birt-Hogg-Dubé Syndrome	1
3	Completed	Treatment	Cardiovascular Abnormalities	1
3	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	2
3	Completed	Treatment	End Stage Liver Diseases / Impaired Renal Function	1
3	Completed	Treatment	Facial Angiofibroma	1
3	Completed	Treatment	Graft Versus Host Disease (GVHD) / Renal Failure	1
3	Completed	Treatment	Graft Versus Host Disease (GVHD) / Transplantation, Kidney	1
3	Completed	Treatment	Hepatocellular,Carcinoma	1
3	Completed	Treatment	Leukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Myelodysplastic Syndromes	1
3	Completed	Treatment	Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)	1
3	Completed	Treatment	Skin Cancers / Transplantation, Kidney	1
3	Completed	Treatment	Transplantation, Kidney	1
3	Completed	Treatment	Transplantation, Renal	2
3	Completed	Treatment	Uvea; Posterior, Disorder / Uveitis; Posterior, Disorder	1
3	Enrolling by Invitation	Not Available	Diabetes, Diabetes Mellitus Type 1 / Islet Transplantation	1
3	Not Yet Recruiting	Treatment	Dyspnea	1
3	Recruiting	Prevention	Arteriovenous Fistulas / Chronic Kidney Failure / Complication of Hemodialysis / Complication of Renal Dialysis / End Stage Kidney Disease / End Stage Renal Disease (ESRD) / ESRD / Vascular Access Complications	1
3	Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
3	Recruiting	Treatment	Polycystic Kidney, Type 1 Autosomal Dominant Disease / Polycystic Kidney, Type 2 Autosomal Dominant Disease	1
3	Recruiting	Treatment	Vascular Malformations	1
3	Terminated	Treatment	Atherosclerosis / Renal Failure	1
3	Terminated	Treatment	End-Stage Renal Disease (ESRD) / Transplantation, Kidney	1
3	Terminated	Treatment	Oral Lichen Planus	1
3	Terminated	Treatment	Transplant, Kidney	1
3	Terminated	Treatment	Transplantation, Liver	1
3	Unknown Status	Prevention	Hepatocellular,Carcinoma	1
3	Unknown Status	Prevention	Transplantation, Kidney	1
3	Unknown Status	Treatment	Lymphangioleiomyomatosis	1
4	Active Not Recruiting	Prevention	Kidney Transplant Rejection	1
4	Active Not Recruiting	Treatment	Pancreas Transplantation / Transplantation, Kidney	1
4	Completed	Not Available	Chronic Kidney Failure / Graft Versus Host Disease (GVHD) / Transplantation, Kidney	1
4	Completed	Not Available	Function of Renal Transplant	1
4	Completed	Health Services Research	Coronary Artery Restenosis / Coronary Heart Disease (CHD)	1
4	Completed	Prevention	Acute Graft Rejection / Delayed Graft Function	1
4	Completed	Prevention	Chronic Hepatitis C Infection	1
4	Completed	Prevention	Rejection, Transplant / Renal Allograft Recipients / Transplant, Kidney	1
4	Completed	Prevention	Rejection, Transplant / Renal Failure	1
4	Completed	Prevention	Skin Neoplasms / Transplantation, Kidney	1
4	Completed	Prevention	Transplantation, Kidney	2
4	Completed	Treatment	Adult Primary Kidney Transplantation	1
4	Completed	Treatment	Ageing / Rejection, Transplant / Renal Failure	1
4	Completed	Treatment	Chronic Kidney Disease (CKD) / Transplantation, Kidney	1
4	Completed	Treatment	Comparative Study / Immunosuppressive Agents	1
4	Completed	Treatment	Coronary Artery Restenosis	1
4	Completed	Treatment	Disorder Related to Renal Transplantation / Infections, Cytomegalovirus	1
4	Completed	Treatment	End-Stage Renal Disease (ESRD)	1
4	Completed	Treatment	Graft Versus Host Disease (GVHD) / Renal Failure	2
4	Completed	Treatment	Inflammatory Reaction	1
4	Completed	Treatment	Kidney Diseases	1
4	Completed	Treatment	Kidney Diseases / Renal Failure	1
4	Completed	Treatment	Primary Renal Allograft	1
4	Completed	Treatment	Rejection, Transplant / Renal Failure / Transplant, Kidney	1
4	Completed	Treatment	Rejection, Transplant / Renal Failure / Transplantation, Kidney	1
4	Completed	Treatment	Renal Angiomyolipomas	1
4	Completed	Treatment	Transplant, Kidney	3
4	Completed	Treatment	Transplantation, Kidney	6
4	Completed	Treatment	Transplantation, Liver	1
4	Completed	Treatment	Transplantation, Renal	1
4	Recruiting	Prevention	Infections, Cytomegalovirus	1
4	Recruiting	Treatment	CCR5 / HIV Disease / HIV Reservoir / Transplant, Kidney	1
4	Recruiting	Treatment	Crohn's Disease (CD)	1
4	Recruiting	Treatment	Refractory Solid Tumors	1
4	Recruiting	Treatment	Transplantation, Kidney	1
4	Terminated	Prevention	Renal Transplant Patients at High-risk for Skin Cancer	1
4	Terminated	Prevention	Skin Cancers / Transplantation, Kidney	1
4	Terminated	Treatment	Kidney Transplant Failure and Rejection	1
4	Unknown Status	Prevention	Immunosuppression / Transplantation, Kidney / Transplantations	2
4	Unknown Status	Treatment	Chronic Allograft Nephropathy (CAN) / Glomerular Filtration Rate (GFR)	1
4	Unknown Status	Treatment	Delayed Graft Function / Slow Graft Function-defined at Creatinine >= 3.0 by Post-op Day 5 Without Requiring Dialysis / Transplant, Kidney	1
4	Unknown Status	Treatment	End Stage Renal Disease (ESRD) / Transplantation, Kidney	1
4	Unknown Status	Treatment	Immunosuppression / Interstitial Fibrosis (IF) / Kidney Failure,Chronic / Transplantations	1
4	Unknown Status	Treatment	Kidney Diseases / Rejection, Transplant	1
4	Unknown Status	Treatment	Transplant, Kidney	1
4	Unknown Status	Treatment	Transplantation, Kidney	2
4	Withdrawn	Not Available	Transplantation, Kidney	1
4	Withdrawn	Treatment	Kidney Graft Dysfunction	1
4	Withdrawn	Treatment	Living Donor Kidney Transplants Patients	1
Not Available	Active Not Recruiting	Prevention	Renal Failure	1
Not Available	Active Not Recruiting	Treatment	Diffuse Parenchymal Lung Diseases / Idiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD)	1
Not Available	Active Not Recruiting	Treatment	Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific	1
Not Available	Completed	Not Available	ADPKD	1
Not Available	Completed	Not Available	Immune Thrombocytopenia	1
Not Available	Completed	Not Available	Immune Thrombocytopenic Purpura ( ITP )	1
Not Available	Completed	Not Available	Transplantation, Kidney	1
Not Available	Completed	Not Available	Transplantation, Renal	1
Not Available	Completed	Not Available	Transplantations	1
Not Available	Completed	Prevention	Absence; Kidney	1
Not Available	Completed	Prevention	Transplant, Kidney	2
Not Available	Completed	Screening	Transplantation, Kidney	1
Not Available	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
Not Available	Completed	Treatment	AML	1
Not Available	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)	1
Not Available	Completed	Treatment	End-Stage Renal Disease (ESRD)	1
Not Available	Completed	Treatment	Posttraumatic Stress Disorders	1
Not Available	No Longer Available	Not Available	Diabetes, Diabetes Mellitus Type 1	2
Not Available	Recruiting	Not Available	Lymphangioleiomyomatosis	1
Not Available	Recruiting	Diagnostic	Acute Rejection of Liver Transplant / Effects of Immunosuppressant Therapy	1
Not Available	Recruiting	Supportive Care	Primary Myelofibrosis / Secondary Myelofibrosis	1
Not Available	Recruiting	Treatment	Haemoglobinopathies congenital / Sickle Cell Disorders	1
Not Available	Recruiting	Treatment	Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia	1
Not Available	Recruiting	Treatment	Tumors, Solid	1
Not Available	Terminated	Not Available	Transplantation, Renal	1
Not Available	Terminated	Treatment	Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory / Recurrent Adult Lymphoblastic Lymphoma / Refractory Acute Lymphoblastic Leukemia / Relapsed Lymphoblastic Leukemia	1
Not Available	Terminated	Treatment	Polycystic Liver Disease (PLD)	1
Not Available	Terminated	Treatment	Port-wine Stains (PWS)	1
Not Available	Unknown Status	Not Available	Acute Rejection of Renal Transplant	1
Not Available	Unknown Status	Treatment	Malignant Neoplasm of Prostate	1
Not Available	Withdrawn	Prevention	Cardiac Allograft Vasculopathy	1

Pharmacoeconomics

Manufacturers

Wyeth pharmaceuticals inc

Packagers

Cardinal Health
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.
Lake Erie Medical and Surgical Supply
Patheon Inc.
Poli Industria Chimica SPA
Wyeth Pharmaceuticals

Dosage forms

Form	Route	Strength
Solution	Oral	1 mg/ml
Tablet	Oral	1.0 mg
Tablet	Oral	2 mg
Tablet	Oral	5 mg
Tablet, coated	Oral	0.5 mg
Tablet, coated	Oral	1 mg
Tablet, coated	Oral	2 mg
Tablet, sugar coated	Oral	.5 mg/1
Tablet, sugar coated	Oral	1 mg/1
Tablet, sugar coated	Oral	2 mg/1
Solution	Oral	1.0 mg
Tablet	Oral	1 mg/1
Tablet	Oral	2 mg/1
Tablet, film coated	Oral	.5 mg/1

Prices

Unit description	Cost	Unit
Rapamune 2 mg tablet	20.59USD	tablet
Rapamune 1 mg/ml Solution	12.19USD	ml
Rapamune 1 mg tablet	11.95USD	tablet
Rapamune 0.5 mg tablet	5.86USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2103571	No	2003-04-29	2012-02-21	Canada
CA2293793	No	2006-07-11	2018-06-11	Canada
US5212155	No	1993-05-18	2010-05-18	US
US5989591	Yes	1998-09-11	2018-09-11	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	4.3	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00173 mg/mL	ALOGPS
logP	4.85	ALOGPS
logP	7.45	ChemAxon
logS	-5.7	ALOGPS
pKa (Strongest Acidic)	9.96	ChemAxon
pKa (Strongest Basic)	-3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	12	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	195.43 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	250.66 m³·mol^-1	ChemAxon
Polarizability	100.46 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	-	0.7841
Blood Brain Barrier	-	0.9599
Caco-2 permeable	-	0.6341
P-glycoprotein substrate	Substrate	0.8052
P-glycoprotein inhibitor I	Inhibitor	0.8564
P-glycoprotein inhibitor II	Inhibitor	0.8021
Renal organic cation transporter	Non-inhibitor	0.8116
CYP450 2C9 substrate	Non-substrate	0.878
CYP450 2D6 substrate	Non-substrate	0.9138
CYP450 3A4 substrate	Substrate	0.7776
CYP450 1A2 substrate	Non-inhibitor	0.9007
CYP450 2C9 inhibitor	Non-inhibitor	0.9125
CYP450 2D6 inhibitor	Non-inhibitor	0.9414
CYP450 2C19 inhibitor	Non-inhibitor	0.9158
CYP450 3A4 inhibitor	Non-inhibitor	0.9333
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9742
Ames test	Non AMES toxic	0.6617
Carcinogenicity	Non-carcinogens	0.9546
Biodegradation	Not ready biodegradable	0.9593
Rat acute toxicity	2.8689 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9831
hERG inhibition (predictor II)	Non-inhibitor	0.8443

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.

Kingdom

Organic compounds

Super Class

Phenylpropanoids and polyketides

Class

Macrolide lactams

Sub Class

Not Available

Direct Parent

Macrolide lactams

Alternative Parents

Alpha amino acid esters / Macrolides and analogues / Cyclohexanols / Piperidines / Oxanes / Tertiary carboxylic acid amides / Carboxylic acid esters / Cyclic alcohols and derivatives / Cyclic ketones / Hemiacetals

Substituents

Macrolide lactam / Alpha-amino acid ester / Macrolide / Alpha-amino acid or derivatives / Cyclohexanol / Oxane / Piperidine / Cyclic alcohol / Tertiary carboxylic acid amide / Cyclic ketone

Molecular Framework

Aliphatic heteropolycyclic compounds

External Descriptors

Polyenes (LMPK06000003 )

Targets

Details

1. Serine/threonine-protein kinase mTOR

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Tfiiic-class transcription factor binding
Specific Function:: Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:: MTOR
Uniprot ID:: P42345
Molecular Weight:: 288889.05 Da

References

Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N: Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010 Mar;1804(3):433-9. doi: 10.1016/j.bbapap.2009.12.001. Epub 2009 Dec 11. [PubMed:20005306 ]
Shuuin T, Karashima H: [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. [PubMed:19620795 ]
Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Peptidyl-prolyl cis-trans isomerase FKBP1A

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: other

General Function:: Type i transforming growth factor beta receptor binding
Specific Function:: Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins....
Gene Name:: FKBP1A
Uniprot ID:: P62942
Molecular Weight:: 11950.665 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462 ]

Details

3. Fibroblast growth factor 2

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: other/unknown

General Function:: Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function:: Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:: FGF2
Uniprot ID:: P09038
Molecular Weight:: 30769.715 Da

References

Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

2. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A5
Uniprot ID:: P20815
Molecular Weight:: 57108.065 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

3. Cytochrome P450 3A7

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A7
Uniprot ID:: P24462
Molecular Weight:: 57525.03 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitorinducer

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
Wacher VJ, Silverman JA, Wong S, Tran-Tau P, Chan AO, Chai A, Yu XQ, O'Mahony D, Ramtoola Z: Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther. 2002 Oct;303(1):308-13. [PubMed:12235265 ]
Arceci RJ, Stieglitz K, Bierer BE: Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992 Sep 15;80(6):1528-36. [PubMed:1381629 ]
Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]

Details

2. Solute carrier organic anion transporter family member 1B1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:: SLCO1B1
Uniprot ID:: Q9Y6L6
Molecular Weight:: 76447.99 Da

References

Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. [PubMed:14530907 ]

Details

3. Multidrug and toxin extrusion protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Monovalent cation:proton antiporter activity
Specific Function:: Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport...
Gene Name:: SLC47A1
Uniprot ID:: Q96FL8
Molecular Weight:: 61921.585 Da

References

Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB: Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009. Epub 2010 Jan 6. [PubMed:20053795 ]

Drug created on June 13, 2005 07:24 / Updated on July 11, 2017 01:59

Get DrugBank to go!

Structure for DB00877 (Sirolimus)

Targets

References

References

References

Enzymes

References

References

References

Transporters

References

References

References